Dataset from A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the
benefit of venetoclax in combination with rituximab compared with bendamustine in combination
with rituximab in participants with relapsed or refractory CLL. Participants will be randomly
assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine +
rituximab (Arm B).